Beta Bionics, Inc. Common Stock (BBNX) — Cash Flow-to-Debt Ratio
Beta Bionics, Inc. Common Stock (BBNX) has a Cash Flow-to-Debt Ratio of -0.25x as of September 2025, meaning its operating cash flow of $-8.73 Million could theoretically repay 0% of its total liabilities ($35.29 Million) in one year. See BBNX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Beta Bionics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2024)
Historical debt coverage capacity for Beta Bionics, Inc. Common Stock across 3 annual periods. Also explore Beta Bionics, Inc. Common Stock annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Beta Bionics, Inc. Common Stock (2022–2024)
Year-by-year debt coverage analysis for Beta Bionics, Inc. Common Stock. For market capitalisation and broader financial context, see BBNX stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.66x | $-48.27 Million | $73.63 Million | ▼ -3.9% |
| 2023 | -0.63x | $-32.45 Million | $51.43 Million | ▲ +76.4% |
| 2022 | -2.67x | $-60.21 Million | $22.53 Million | — |